देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
DARUNAVIR (DARUNAVIR ETHANOLATE)
JANSSEN INC
J05AE10
DARUNAVIR
100MG
SUSPENSION
DARUNAVIR (DARUNAVIR ETHANOLATE) 100MG
ORAL
200ML
Prescription
HIV PROTEASE INHIBITORS
Active ingredient group (AIG) number: 0151656007; AHFS:
APPROVED
2013-11-19
_ _ _Page 1 of 93_ _ _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR PREZISTA ® darunavir tablets 75 mg, 150 mg, 600 mg, 800 mg darunavir oral suspension 100 mg/mL (as darunavir ethanolate) Human Immunodeficiency Virus (HIV) Protease Inhibitor Janssen Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 www.janssen.com/canada Date of Initial Authorization: Jul 27, 2006 Date of Revision: October 14, 2022 Submission Control Number: 264786 © 2022 Janssen Inc. All trademarks used under license _ _ _Page 2 of 93_ _ _ RECENT MAJOR LABEL CHANGES None at the time of the most recent authorization TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .................................................................................... 2 TABLE OF CONTENTS ......................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION.............................................................. 4 1 INDICATIONS............................................................................................................. 4 1.1 Pediatrics......................................................................................................... 4 1.2 Geriatrics ......................................................................................................... 4 2 CONTRAINDICATIONS .............................................................................................. 4 4 DOSAGE AND ADMINISTRATION ............................................................................. 5 4.1 Dosing Considerations ..................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment.................................................. 5 4.5 Missed Dose .................................................................................................... 8 5 OVERDOSAGE ............................................... पूरा दस्तावेज़ पढ़ें